Hamdy Ronald C, Kiebzak Gary M
Osteoporosis Center, East Tennessee State University, Johnson City, TN, USA; VAMC, Johnson City, TN, USA.
J Clin Densitom. 2009 Apr-Jun;12(2):158-61. doi: 10.1016/j.jocd.2008.12.003. Epub 2009 Feb 8.
The World Health Organization fracture risk assessment tool (FRAX) uses clinical risk factors to predict the patient's 10-yr probability of sustaining a hip or other major osteoporosis-related fracture. Inclusion of the femoral neck T-score is optional in the calculation. We evaluated the impact of including the T-score in the calculation of fracture risk and resultant treatment recommendation. We retrospectively reviewed charts of 180 white women scanned on a Hologic dual-energy X-ray absorptiometry (DXA). FRAX scores were calculated with T-scores (FRAX+) and without T-scores (FRAX-). We compared the National Osteoporosis Foundation (NOF) treatment recommendations (>or=20% risk of a major osteoporotic fracture or >or=3% risk of hip fracture for osteopenic patients) between FRAX+ and FRAX- scores. Agreement between FRAX+ and FRAX- was 89.4%. Disagreement occurred in 2 distinct subgroups of patients (10.6% of cases), that is, FRAX+ scores exceeded the NOF recommended treatment thresholds and FRAX- scores did not, or vice versa. One subgroup comprised older patients with normal T-scores for whom FRAX- scores exceeded the treatment threshold. The second subgroup comprised younger patients with high body mass index (BMI) and low T-scores for whom FRAX- scores did not exceed the treatment threshold. FRAX scores generated without T-scores may lead to treatment recommendations for patients who have normal bone mineral density and no treatment recommendations for patients who have osteoporosis. T-scores should be used for optimal application of FRAX.
世界卫生组织骨折风险评估工具(FRAX)利用临床风险因素来预测患者在10年内发生髋部骨折或其他与骨质疏松症相关的主要骨折的概率。在计算中纳入股骨颈T值是可选择的。我们评估了在骨折风险计算及由此得出的治疗建议中纳入T值的影响。我们回顾性分析了180名接受Hologic双能X线吸收测定法(DXA)扫描的白人女性的病历。分别计算了包含T值的FRAX评分(FRAX+)和不包含T值的FRAX评分(FRAX-)。我们比较了FRAX+评分与FRAX-评分之间的美国国家骨质疏松基金会(NOF)治疗建议(骨质疏松症患者发生主要骨质疏松性骨折的风险≥20%或髋部骨折风险≥3%)。FRAX+与FRAX-之间的一致性为89.4%。在两个不同的患者亚组中出现了不一致情况(占病例的10.6%),即FRAX+评分超过了NOF推荐的治疗阈值而FRAX-评分未超过,或者反之。一个亚组包括T值正常的老年患者,其FRAX-评分超过了治疗阈值。第二个亚组包括体重指数(BMI)高且T值低的年轻患者,其FRAX-评分未超过治疗阈值。不包含T值生成的FRAX评分可能会导致对骨密度正常的患者给出治疗建议,而对患有骨质疏松症的患者不给出治疗建议。为了最佳应用FRAX,应使用T值。